Relationship of atrial fibrillation with obesity and chronic heart failure
https://doi.org/10.52727/2078-256X-2023-19-1-28-34
Abstract
The article presents the current state of the problem of atrial fibrillation as the most widespread cardiac rhythm disorder, the occurrence of which significantly worsens the quality of life of patients and reduces their life expectancy. Undoubtedly, a significant number of patients with atrial fibrillation suffer from obesity and heart failure. The review article reviews the understanding of the fundamental pathogenetic mechanisms of atrial fibrillation and the associated changes in the cellular, molecular, electrophysiological, and structural architecture of the atria. Information on the topic from publications based on PubMed, Google Scholar, and eLIBRARY databases was used, with a depth of coverage of 5 years.
About the Authors
A. D. Sharonin
Novosibirsk State University
Russian Federation
Russian Federation
Alexandr D. Sharonin, master of the 2nd year
1, Pirogov str., Novosibirsk, 630090
N. G. Lozhkina
Federal State Budgetary Scientific Institution “Federal Research Center for Fundamental and Translational Medicine”
Russian Federation
Russian Federation
Nataliya G. Lozhkina, doctor of medical sciences, professor, head of clinical and experimental cardiology group, professor of the immunology; cardiologist, supervisor of department for treatment of patients with acute coronary syndrome of RCVC № 1 of Municipal Clinical Hospital № 1
2, Timakov str., Novosibirsk, 630117
References
1. Friberg J., Buch P., Scharling H., Gadsbphioll N., Jensen G.B. Rising rates of hospital admissions for atrial fibrillation. Epidemiology, 2003; 14 (6): 666–672. doi: 10.1097/01.ede.0000091649.26364.c0
2. Carlisle M.A., Fudim M., DeVore A.D., Piccini J.P. Heart failure and atrial fibrillation. Like fire and fury. JACC Heart Fail., 2019; 7 (6): 447–456. doi: 10.1016/j.jchf.2019.03.005
3. Migdady I., Russman A., Buletko A.B. Atrial Fibrillation and Ischemic Stroke: A Clinical Review. Semin Neurol., 2021; 41 (4): 348–364. doi: 10.1055/s-0041-1726332
4. Elagizi A., Kachur S., Lavie C.J., Carbone S., Pandey A., Ortega F.B., Milani R.V. An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog. Cardiovasc. Dis., 2018; 61 (2): 142–150. doi: 10.1016/j.pcad.2018.07.003. Epub 2018 Jul 5. PMID: 29981771.
5. Wijesurendra R.S., Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc. Res., 2015; 105 (3): 238–247. doi: 10.1093/cvr/cvv001. Epub 2015 Jan 12.
6. Wijesurendra R.S., Casadei B. Mechanisms of atrial fibrillation. Heart, 2019; 105 (24): 1860–1867. doi: 10.1136/heartjnl-2018-314267
7. Chung H.Y., Kim D.H., Lee E.K., Chung K.W., Chung S., Lee B., Seo A.Y., Chung J.H., Jung Y.S., Im E., Lee J., Kim N.D., Choi Y.J., Im D.S., Yu B.P. Redefining Chronic Inflammation in Aging and AgeRelated Diseases: Proposal of the Senoinflammation Concept. Aging. Dis., 2019; 10 (2): 367–382. doi: 10.14336/AD.2018.0324. PMID: 31011483; PMCID: PMC6457053.
8. Linthout S.V., Tschöpe C. Inflammation – Cause or Consequence of Heart Failure or Both? Curr. Heart Fail. Rep., 2017; 14 (4): 251–265. Published online 2017 Jun 30. doi: 10.1007/s11897-017-0337-9
9. Bosch N.A., Cimini J., Walkey A.J. Atrial Fibrillation in the ICU. Chest, 2018; 154 (6): 1424–1434. doi: 10.1016/j.chest.2018.03.040. Epub 2018 Apr 6. PMID: 29627355; PMCID: PMC6335260.
10. Baykaner T., Rogers A.J., Meckler G.L., Zaman J., Navara R., Rodrigo M., Alhusseini M., Kowalewski C.A.B., Viswanathan M.N., Narayan S.M., Clopton P., Wang P.J., Heidenreich P.A. Clinical Implications of Ablation of Drivers for Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circ. Arrhythm. Electrophysiol., 2018; 11 (5): e006119. doi: 10.1161/CIRCEP.117.006119. PMID: 29743170; PMCID: PMC6474343.
11. Lubitz S.A., Yin X., Fontes J.D., Magnani J.W., Rienstra M., Pai M., Villalon M.L., Vasan R.S., Pencina M.J., Levy D., Larson M.G., Ellinor P.T., Benjamin E.J. Association between familial atrial fibrillation and risk of new-onset atrial fibrillation. JAMA, 2010; 304 (20): 2263–2269. doi: 10.1001/jama.2010.1690. Epub 2010 Nov 13.
12. Roselli C., Chaffin M.D., Weng L.-C., Aeschbacher S., Ahlberg G., Albert C.M., Almgren P., Alonso A., Anderson C.D., Aragam K.G. Multi-ethnic genome-wide association study for atrial fibrillation. Nat. Genet., 2018; 50 (9): 1225–1233. doi: 10.1038/s41588-018-0133-9
13. Nielsen J.B., Thorolfsdottir R.B., Fritsche L.G., Zhou W., Skov M.W., Graham S.E., Herron T.J., McCarthy S., Schmidt E.M., Sveinbjornsson G., Surakka I., Mathis M.R. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology, 2018; 50 (9): 1234–1239. doi: 10.1038/s41588-018-0171-3. Epub 2018 Jul 30.
14. Никулина С.Ю., Шишкова К.Ю., Шульман В.А., Чернова А.А., Максимов В.Н. Роль SNP-маркеров хромосомы 10 в патогенезе фибрилляции предсердий. Рос. кардиол. журн., 2021; 26 (7): 4148. https://doi.org/10.15829/1560-4071-2021-4148
15. Аксютина Н.В., Шульман В.А., Никулина С.Ю., Назаров Б.В., Максимов В.Н., Плита Е.В., Котловский М.Ю., Верещагина Т.Д. Клинико-генетический рискометр расчета развития ишемического инсульта у больных с фибрилляцией предсердий. Рос. кардиол. журн., 2015; 10: 42–45. https://doi.org/10.15829/1560-4071-2015-10-42-45
16. Wong C.X., Sun M.T., Odutayo A., Emdin C.A., Mahajan R., Lau D.H., Pathak R.K., Wong D.T., Selvanayagam J.B., Sanders P., Clarke R. Associations of Epicardial, Abdominal, and Overall Adiposity With Atrial Fibrillation. Circ. Arrhythm. Electrophysiol., 2016; 9 (12): e004378. doi: 10.1161/CIRCEP.116.004378
17. Park S.S., Jung J., Mintz G.S., Jin U., Park J.S., Park B., Shin H.B., Seo K.W., Yang H.M., Lim H.S., Choi B.J., Yoon M.H., Shin J.H., Tahk S.J., Choi S.Y. Epicardial Adipose Tissue Thickness Is Related to Plaque Composition in Coronary Artery Disease. Diagnostics (Basel), 2022; 12 (11): 2836. doi: 10.3390/diagnostics12112836. PMID: 36428896; PMCID: PMC9689801.
18. Chekakie M.O.A., Welles C.C., Metoyer R., Ibrahim A., Shapira A.R., Cytron J., Santucci P., Wilber D.J., Akar J.G. Pericardial fat is independently associated with human atrial fibrillation. J. Am. Coll. Cardiol., 2010; 56 (10): 784–788. doi: 10.1016/j.jacc.2010.03.071
19. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat. Rev. Cardiol., 2022; 19 (9): 593–606. doi: 10.1038/s41569-022-00679-9. Epub 2022 Mar 16. PMID: 35296869; PMCID: PMC8926097.
20. King R.J., Ajjan R.A. Vascular risk in obesity: Facts, misconceptions and the unknown. Diab. Vasc. Dis. Res., 2017; 14 (1): 2–13. doi: 10.1177/1479164116675488. Epub 2016 Nov 14. PMID: 27941051.
21. Bruins P., Velthuis H., Yazdanbakhsh A.P., Jansen P.G., Hardevelt F.W., Beaumont E.M., Wildevuur C.R., Eijsman L., Trouwborst A., Hack C.E. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation, 1997; 96 (10): 3542–3548. doi: 10.1161/01.cir.96.10.3542
22. Truong C.D., Nguyen B.T., van Cong Tran T. Prediction of risk factors for recurrence of atrial fibrillation in patients with arterial hypertension. Int. J. Cardiovasc. Imaging, 2021; 37 (12): 3413–3421. doi: 10.1007/s10554-021-02331-y. Epub 2021 Jul 3. PMID: 34216329.
23. Tai M., Shi H., Wang H., Ma X., Gao M., Chang Q., Li F., Zeng Q., Shi Y., Guo Y. Pilot study of peripheral blood chemokines as biomarkers for atrial fibrillation-related thromboembolism and bleeding in elderly patients. Front Public. Health, 2022; 10: 844087. doi: 10.3389/fpubh.2022.844087. PMID: 36211709; PMCID: PMC9538109.
24. Scott L., Jr., Li N. Role of Inflammatory Signaling in Atrial Fibrillation. Int. J. Cardiol., 2019; 287: 195–200. Published online 2018 Oct 4. doi: 10.1016/j.ijcard.2018.10.020
25. Aronson J.K., Ferner R.E. Biomarkers-A General Review Curr Protoc. Pharmacol, 2017; 76: 9.23.1– 9.23.17. doi: 10.1002/cpph.19
26. Calkins H., Hindricks G., Cappato R., Kim Y.H., Saad E.B., Aguinaga L., Akar J.G., Badhwar V., Brugada J., Camm J., Chen P.S., Chen S.A., Chung M.K., Nielsen J.C., Curtis A.B., Davies D.W., Day J.D., d’Avila A., de Groot NMSN, di Biase L., Duytschaever M., Edgerton J.R., Ellenbogen K.A., Ellinor P.T., Ernst S., Fenelon G., Gerstenfeld E.P., Haines D.E., Haissaguerre M., Helm R.H., Hylek E., Jackman W.M., Jalife J., Kalman J.M., Kautzner J., Kottkamp H., Kuck K.H., Kumagai K., Lee R., Lewalter T., Lindsay B.D., Macle L., Mansour M., Marchlinski F.E., Michaud G.F., Nakagawa H., Natale A., Nattel S., Okumura K., Packer D., Pokushalov E., Reynolds M.R., Sanders P., Scanavacca M., Schilling R., Tondo C., Tsao H.M., Verma A., Wilber D.J., Yamane T. 2017 HRS/ EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm., 2017; 14 (10): e275–e444. doi: 10.1016/j.hrthm.2017.05.012. Epub 2017 May 12. PMID: 28506916; PMCID: PMC6019327.
27. Ono K., Iwasaki Y.K., Akao M., Ikeda T., Ishii K., Inden Y., Kusano K., Kobayashi Y., Koretsune Y., Sasano T., Sumitomo N., Takahashi N., Niwano S., Hagiwara N., Hisatome I., Furukawa T., Honjo H., Maruyama T., Murakawa Y., Yasaka M., Watanabe E., Aiba T., Amino M., Itoh H., Ogawa H., Okumura Y., Aoki-Kamiya C., Kishihara J., Kodani E., Komatsu T., Sakamoto Y., Satomi K., Shiga T., Shinohara T., Suzuki A., Suzuki S., Sekiguchi Y., Nagase S., Hayami N., Harada M., Fujino T., Makiyama T., Maruyama M., Miake J., Muraji S., Murata H., Morita N., Yokoshiki H., Yoshioka K., Yodogawa K., Inoue H., Okumura K., Kimura T., Tsutsui H., Shimizu W. Japanese Circulation Society and; Japanese Heart Rhythm Society Joint Working Group. JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. J. Arrhythm., 2022; 38 (6): 833–973. doi: 10.1002/joa3.12714. PMID: 36524037; PMCID: PMC9745564.
28. Pauklin P., Zilmer M., Eha J., Tootsi K., Kals M., Kampus P. Markers of Inflammation, Oxidative Stress, and Fibrosis in Patients with Atrial Fibrillation. Oxid. Med. Cell Longev., 2022; 2022: 4556671. doi: 10.1155/2022/4556671. PMID: 35651726; PMCID: PMC9150993.
29. Korantzopoulos P., Letsas K.P., Tse G., Fragakis N., Goudis C.A., Liu T. Inflammation and atrial fibrillation: A comprehensive review. J. Arrhythm., 2018; 34 (4): 394–401. doi: 10.1002/joa3.12077. PMID: 30167010; PMCID: PMC6111477.
30. Ihara K., Sasano T. Role of Inflammation in the Pathogenesis of Atrial Fibrillation. Front. Physiol., 2022; 13: 862164. doi: 10.3389/fphys.2022.862164. PMID: 35492601; PMCID: PMC9047861.
31. Abe I., Teshima Y., Kondo H., Kaku H., Kira S., Ikebe Y., Saito S., Fukui A., Shinohara T., Yufu K., Nakagawa M., Hijiya N., Moriyama M., Shimada T., Miyamoto S., Takahashi N. Association of fibrotic remodeling and cytokines/chemokines content in epicardial adipose tissue with atrial myocardial fibrosis in patients with atrial fibrillation. Heart Rhythm., 2018; 15 (11): 1717–1727. doi: 10.1016/j.hrthm.2018.06.025. Epub 2018 Jun 13. PMID: 29908372.
32. Li J., Solus J., Chen Q., Rho Y.H., Milne G., Stein M., Darbar D. The Role of Inflammation and Oxidative Stress in Atrial Fibrillation. Heart Rhythm., 2010; 7 (4): 438–444. Published online 2009 Dec 24. doi: 10.1016/j.hrthm.2009.12.009
33. Nakagawa Y., Nishikimi T., Kuwahara K. Atrial and brain natriuretic peptides: Hormones secreted from the heart. Peptides, 2019; 111: 18–25. doi: 10.1016/j. peptides.2018.05.012. Epub 2018 May 31. PMID: 29859763.
34. Turkoglu E.I., Kircicegi Cicekdag E.C. Heart failure with preserved ejection fraction, atrial fibrillation, and increased NT-proBNP levels: An emergent clinical dilemma. Herz, 2021; 46 (Suppl 2): 191–197. English. doi: 10.1007/s00059-020-04981-5. Epub 2020 Sep 30. PMID: 32997152.
35. Patton K.K., Ellinor P.T., Heckbert S.R., Christenson R.H., DeFilippi C., Gottdiener J.S., Kronmal R.A. N-terminal pro-B-type Natriuretic Peptide is a Major Predictor of the Development of Atrial Fibrillation: The Cardiovascular Health Study. Circulation, 2009; 120 (18): 1768–1774. Published online 2009 Oct 19. doi: 10.1161/CIRCULATIONAHA.109.873265
36. Blaha M.J., DeFilippis A.P. Multi-Ethnic Study of Atherosclerosis (MESA): JACC Focus Seminar 5/8. J. Am. Coll. Cardiol., 2021; 77 (25): 3195–3216. doi: 10.1016/j.jacc.2021.05.006. PMID: 34167645; PMCID: PMC8091185.
37. Jumeau C., Rupin A., Chieng-Yane P., Mougenot N., Zahr N., David-Dufilho M., Hatem S.N. Direct Thrombin Inhibitors Prevent Left Atrial Remodeling Associated With Heart Failure in Rats. JACC Basic. Transl. Sci., 2016; 1 (5): 328–339. doi: 10.1016/j.jacbts.2016.05.002. PMID: 27642643; PMCID: PMC5012373.
38. EDORA Investigators. Effect of DrOnedarone on atrial fibrosis progression and atrial fibrillation recurrence postablation: Design of the EDORA randomized clinical trial. J. Cardiovasc. Electrophysiol., 2021; 32 (12): 3203–3210. doi: 10.1111/jce.15274. Epub 2021 Nov 2. PMID: 34664772; PMCID: PMC9298087.
Review
For citations:
Sharonin A.D., Lozhkina N.G. Relationship of atrial fibrillation with obesity and chronic heart failure. Ateroscleroz. 2023;19(1):28-34. (In Russ.) https://doi.org/10.52727/2078-256X-2023-19-1-28-34
Views:
363
Email this article 